Table 2.
Overview of authorized COVID-19 vaccines worldwide
| Vaccine | Sponsor | Vaccine type | Administration |
Approval information |
Efficacy evidence |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Storage | Dosage | Date | Age range | Approval countries | Confirmatory evidence | Sample size | Efficacy | |||
| Gam-COVID-Vac Lyo | Gamaleya Research Institute | VVNR | stable at 2–8°C | 2 doses, 0/21d | 2020/8/10 | Unclarified | 68 | Yes | 21,977 | 92% |
| BBIBP-CorV* | Sinopharm | IV | stable at 2–8°C | 2 doses, 0/21d | 2020/8/12 | Unclarified | 41 | Yes | 25,463 | 78.1% |
| EpiVacCorona | Federal Budgetary Research Institution | PS | Unclarified | 2 doses, 0/21-28d | 2020/10/13 | ≥18 y old | 2 | Unreported | / | / |
| BNT162b2 | Pfizer/BioNtech/ Fosun Pharma | RNA | Stable at −80 ~ −60°C; 2 ~ 8°C for 1 month | 2 doses, 0/21d | 2020/11/20 | ≥16 y old | 84 | Yes | 43,548 | 95% |
| mRNA-1273 | Moderna/NIAID | RNA | Stable at −50 ~ −15°C; 2 ~ 8°C for 30 d; 8 ~ 25°C for 24 hours | 2 doses, 0/28d | 2020/12/18 | ≥18 y old | 46 | Yes | 30,420 | 94% |
| AZD-1222 | Oxford Universty/ AstraZeneca | VVNR | stable at 2–8°C | 2 doses, 0/4-12 w | 2020/12/30 | ≥18 y old | 98 | Yes | 11,636 8534 |
70% 70% |
| COVAXIN | Bharat Biotech | IV | stable at 2–8°C | 2 doses, 0/28d | 2021/1/3 | Unclarified | 9 | Yes | 25,800 | 81% |
| CoronaVac* | Sinovac | IV | stable at 2–8°C | 2 doses, 0/14d | 2021/1/11 | Unclarified | 25 | Unreported | / | / |
| QAZCOVID-IN | Unclarified | IV | Unclarified | Unclarified | 2021/1/113 | Unclarified | 1 | Unreported | / | / |
| CoviVac | Russian Academy of Sciences | IV | Unclarified | Unclarified | 2021/2/20 | Unclarified | 1 | Yes | 12,396 7371 | 51% 91% |
| Unclarified* | Sinopharm | IV | stable at 2–8°C | 2 doses, 0/21d | 2021/2/25 | Unclarified | 1 | Yes | 25,480 | 72.8% |
| Ad5-nCoV* | CanSino BIO | VVNR | stable at 2–8°C | 1 dose | 2021/2/25 | Unclarified | 5 | Unreported | / | / |
| Ad26.COV2.S | Janssen | VVNR | Stable at −20°C; 2 ~ 8°C for 3 months | 1 dose | 2021/3/1 | ≥18 y old | 41 | Unreported | / | / |
| ZF2001 | Zhifei/Chinese Academy of Sciences | PS | stable at 2–8°C | 3 doses, 0/30/60d | 2021/3/1 | Unclarified | 2 | Unreported | / | / |
| KCONVAC | Beijing Minhai Biotechnology Co | IV | Unclarified | 2 doses, 0/28d | 2021/5/14 | ≥18 y old | 1 | Unreported | / | / |
* Vaccines with an asterisk were conditionally approved in China, and the others were approved for emergency use authorization only. Viral vector non-replicating is abbreviated as VVNR; Inactivated virus is abbreviated as IV; Protein subunit is abbreviated as PS.